comparemela.com

Latest Breaking News On - Biopharm company - Page 4 : comparemela.com

Global Doxorubicin Market to Reach $1 3 Billion by 2026

Worldwide Liposomal Doxorubicin Industry to 2026 - Featuring Baxter International, Cipla and Pfizer Among Others

Microscopic Polyangiitis Market: Global Industry Analysis and Opportunity Assessment 2021-2028 | Top

Overview of Global Microscopic Polyangiitis Market:An international Microscopic Polyangiitis Market report covers a Market overview and the growth prospects of the Market. The current environment of the Healthcare industry and the key trends determining the Market are presented in the report. The Market report is a.

Investegate |PAION AG Announcements | PAION AG: PAION GRANTS EXCLUSIVE LICENSE TO TTY BIOPHARM FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN TAIWAN

Investegate |PAION AG Announcements | PAION AG: PAION GRANTS EXCLUSIVE LICENSE TO TTY BIOPHARM FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN TAIWAN
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Taiwan recalls cancer drugs containing extraneous material

Taiwan recalls cancer drugs containing extraneous material 01/19/2021 03:45 PM A TTY Biopharm production line. CNA file photo Taipei, Jan. 19 (CNA) A total of 9,000 cancer drugs manufactured by the Taiwanese company TTY Biopharm Company Limited are being recalled because they were found to contain extraneous material, Taiwan s Food and Drug Administration (FDA) said Tuesday. The drugs include Gemmis injection 38 mg/ml, which is usually used in combination with other medicines such as Gemcitabine and paclitaxel to treat cancer of the lungs, pancreas, bladder and breast in specific cases, the FDA said. The contamination of the 9,000 cancer drugs with extraneous material was discovered after a hospital reported such findings to the FDA in December 2020, said Hung Kuo-teng (洪國登), head of the FDA s Medicinal Products Division.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.